Treatment of Obstructive Sleep Apnea with Tirzepatide

Clinical Recommendations

Weight loss is strongly recommended as first-line therapy for all overweight and obese patients with OSA, as obesity is the primary modifiable risk factor for this condition, according to the American College of Physicians, as published in the Annals of Internal Medicine 1, 2, 3
CPAP remains the gold standard initial therapy for patients diagnosed with OSA, showing superior efficacy in reducing apnea-hypopnea index (AHI), arousal index, and oxygen desaturation while improving oxygen saturation, as noted in the Annals of Internal Medicine 1, 2
The European Respiratory Society guidelines note a trend toward improvement after weight reduction, though historically this has been difficult to achieve and maintain with lifestyle modifications alone, as published in the European Respiratory Journal 4, 5
Pharmacologic agents evaluated as primary OSA treatments lack sufficient evidence and should not be prescribed for OSA treatment, according to the American College of Physicians, as published in the Annals of Internal Medicine 1, 2

Treatment Alternatives

Consider mandibular advancement devices as alternatives for patients who prefer them or experience CPAP adverse effects, particularly in mild to moderate OSA, as recommended by the American Academy of Sleep Medicine, as published in the Journal of Clinical Sleep Medicine 6, 1

Zepbound's Role in Sleep Apnea Management

Clinical Context and Positioning

The European Respiratory Society recommends weight loss as first-line therapy for all overweight and obese patients with OSA, but it has been difficult to achieve and maintain with lifestyle modifications alone 7
Zepbound represents a unique role as the first FDA-approved pharmacologic agent specifically indicated for moderate to severe OSA with obesity, whereas previous pharmacologic agents lacked sufficient evidence and were not recommended 8
The European Respiratory Society previously recommended carbonic anhydrase inhibitors only in research contexts due to limited evidence and lack of approved labeling, highlighting the need for effective treatments like Zepbound 9, 7, 10

Treatment of Obstructive Sleep Apnea with Zepbound

Introduction to Zepbound Therapy

The American College of Physicians recommends weight loss as a first-line therapy for overweight and obese patients with obstructive sleep apnea (OSA), and Zepbound (tirzepatide) provides a pharmacologic solution to achieve this, as supported by evidence from the Annals of Internal Medicine 11
Weight reduction has been shown to improve OSA, and Zepbound addresses the underlying pathophysiology through weight loss, according to the European Respiratory Journal 12

Treatment Algorithm for OSA

The American College of Physicians suggests initiating Zepbound alongside CPAP therapy for obese patients with moderate to severe OSA, as CPAP remains the gold standard for reducing apnea-hypopnea index, arousal index, and oxygen desaturation, as recommended by the Annals of Internal Medicine 11
CPAP demonstrates superior efficacy in improving sleep study measures compared to other interventions, but Zepbound addresses the underlying pathophysiology through weight loss, as reported in the Annals of Internal Medicine 13

Alternative Treatments for OSA

Mandibular advancement devices (MADs) are recommended as first-line alternatives for mild to moderate OSA in patients who refuse or cannot tolerate CPAP, according to the Annals of Internal Medicine 11, 13
Positional therapy is inferior to CPAP and has poor long-term compliance, as stated in the European Respiratory Journal 12

Monitoring and Follow-Up

Monitoring for CPAP adherence is critical for effective OSA treatment and cardiovascular risk reduction, as emphasized by the Annals of Internal Medicine 11, 13

Tirzepatide Use in Patients with Sleep Apnea

Primary Indication and Patient Selection

Tirzepatide is indicated for patients with moderate-to-severe OSA (AHI ≥15 events/hour) who have obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities, according to the Anaesthesia guideline society 14

Clinical Evidence Supporting Use

Mean weight loss ranges from 15-20.9% at 72 weeks depending on dose (5-15 mg) with tirzepatide, which is substantially greater than other GLP-1 receptor agonists, as reported by the Anaesthesia and JAMA guideline societies 14, 15

Peri-operative Management

The American Society of Anesthesiologists recommends considering the delayed gastric emptying effects of tirzepatide when planning anesthesia, though the magnitude of aspiration risk with chronic use remains uncertain due to potential tachyphylaxis, according to the Anaesthesia guideline society 16
The 2025 multidisciplinary consensus recommends individualized peri-operative management based on drug characteristics, patient profile, procedure type, and anesthetic technique rather than blanket cessation, as stated by the Anaesthesia guideline society 16

Contraindications and Cautions

The Anaesthesia guideline society recommends avoiding tirzepatide in patients with gastroparesis due to further delayed gastric emptying 14
The Anaesthesia guideline society suggests monitoring for cardiac arrhythmia/tachycardia with tirzepatide and considering beta-blockers if symptomatic 14
The Anaesthesia guideline society advises screening for gallbladder disorders with tirzepatide, though symptomatic disease is unusual 14
Long-term use of tirzepatide is necessary, as discontinuation leads to weight regain, with a mean 6.9% regain in the STEP 4 trial after stopping semaglutide, as reported by the JAMA guideline society 15

Pharmacologic and Non-Pharmacologic Treatment for Obstructive Sleep Apnea

Non-Pharmacologic Alternatives

The American Academy of Sleep Medicine recommends mandibular advancement devices (MADs) as first-line alternative for mild to moderate OSA (AHI <30), showing equivalent patient-related outcomes to CPAP despite less AHI reduction 17
Hypoglossal nerve stimulation is suggested for patients with BMI <32 kg/m² who cannot adhere to PAP therapy, requiring strict eligibility criteria including absence of complete concentric collapse at the soft palate level confirmed by drug-induced sleep endoscopy 17
Maxillomandibular advancement surgery can be considered for patients who cannot tolerate or are not appropriate candidates for other recommended therapies, particularly for severe OSA with anatomic abnormalities 17

Treatment to Avoid

Oxygen therapy as stand-alone treatment is suggested against for patients with OSA who cannot tolerate other recommended therapies, due to lack of efficacy in treating the underlying obstruction 17
Topical nasal steroids should not be routinely used for the sole purpose of improving PAP adherence in patients without nasal congestion 17

Clinical Algorithm

The American Academy of Sleep Medicine recommends optimizing CPAP therapy with educational, behavioral, and supportive interventions, mask refitting, pressure adjustments, and heated humidification before considering alternative therapies 17

Current Treatment Options for Obstructive Sleep Apnea

Primary Treatment Algorithm

The American Thoracic Society recommends CPAP as the definitive treatment for moderate to severe symptomatic OSA, showing the greatest reduction in AHI, arousal index, and oxygen desaturation while improving oxygen saturation 18, 19, 20
Weight loss to BMI ≤25 kg/m² is strongly recommended for all overweight/obese OSA patients, as obesity is the primary modifiable risk factor and weight reduction improves breathing patterns, sleep quality, and daytime sleepiness 18, 19, 20
Physical exercise should be prescribed regardless of weight status 18, 19, 20
Avoid alcohol and sedatives before bedtime to prevent upper airway muscle relaxation 18, 19, 20
Implement positional therapy using positioning devices for position-dependent OSA, keeping patients in non-supine positions to improve AHI 18, 19, 20
Vibratory positional therapy can be used in mild to moderate position-dependent OSA as an alternative to CPAP 21

Alternative Treatments for CPAP-Intolerant Patients

Mandibular advancement devices (MADs) are the preferred first-line alternative for mild to moderate OSA without comorbidities, or for severe OSA patients who are CPAP-intolerant 18, 19, 20
Although CPAP is superior in normalizing AHI and oxygen parameters, MADs demonstrate comparable effects on symptoms, quality of life, daytime sleepiness, general physical/mental health, and nocturia 18, 19
MADs show better adherence rates than CPAP in OSA patients 18, 19
Custom-made dual-block MADs have the strongest evidence among oral appliances 21
Hypoglossal nerve stimulation (HNS) is conditionally recommended for selected symptomatic OSA patients with BMI <32 kg/m² who have failed or not tolerated CPAP 18, 19, 20, 21

Surgical Options

Otolaryngologic surgery should be reserved for specific anatomic cases 18, 19, 20
Maxillomandibular advancement (MMO) may be an alternative for patients experiencing CPAP failure 21
Uvulopalatopharyngoplasty (UPPP), laser-assisted uvulopalatoplasty, radiofrequency ablation, and combination procedures have insufficient evidence for routine recommendation 22

Multidisciplinary Approach

Treatment decisions should always be discussed by a multidisciplinary team including qualified dentists, sleep unit specialists, and sleep physicians 18, 19, 20

Key Clinical Pitfalls

Do not use AHI alone for treatment decisions; consider hypoxic burden, hypoxia load, obstruction severity, and symptom/comorbidity phenotypes 19, 20

Pharmacologic Management of Obstructive Sleep Apnea – Evidence‑Based Recommendations

Primary OSA Treatment – Pharmacologic Agents Not Recommended

Drug therapy is not recommended as a primary treatment for obstructive sleep apnea; the European Respiratory Society (ERS) guidelines give a strong recommendation against using medications as the sole therapy for OSA patients. 23, 24, 25
There is no evidence that any medication benefits an unselected OSA population when used alone; pharmacologic agents have not demonstrated efficacy as standalone therapy in guideline‑based studies. 23

Adjunctive Pharmacologic Therapies – Limited or No Efficacy

Protriptyline does not improve respiratory indices and has no place in routine OSA management; minor improvements in daytime symptoms were reported in only 2 of 3 trials and are likely due to nonspecific alerting effects rather than true respiratory benefit. (Evidence: insufficient) 26, 23
Paroxetine (an SSRI) fails to improve daytime symptoms despite achieving a modest reduction in apnea‑hypopnea index (AHI); the clinical relevance of the AHI change is limited without symptom improvement. (Evidence: insufficient) 26, 23
Mirtazapine cannot be recommended for OSA because multicenter trials did not reproduce early positive findings and the drug caused adverse effects such as increased sleepiness and weight gain, outweighing any potential benefit. (Evidence: insufficient) 26, 23, 24
Acetazolamide has no role in routine OSA management; studies show no impact on daytime sleepiness and poor long‑term tolerability, making it unsuitable for standard care. (Evidence: insufficient) 26, 23

Alternative Non‑Pharmacologic Options with Evidence

Positional therapy can achieve moderate reductions in AHI for carefully selected younger patients with low baseline AHI and minimal obesity, but it remains inferior to continuous positive airway pressure (CPAP) in overall efficacy. (Evidence: moderate) 25

Gabapentin Contraindicated in Suspected Obstructive Sleep Apnea

Weight Gain and OSA Risk

Anticonvulsant medications, including gabapentin, are linked to significant weight gain, which can increase adipose tissue around the airway and worsen pharyngeal collapsibility, thereby inducing or aggravating obstructive sleep apnea (OSA) 27.
Obesity is the primary modifiable risk factor for OSA; roughly 70 % of individuals with OSA are obese, and about 40 % of obese adults have OSA 27.

Lack of Therapeutic Evidence

There is no clinical evidence supporting gabapentin as an effective treatment for sleep‑disordered breathing; the drug does not improve OSA outcomes when used alone 27.

Clinical Implications of Prescribing Gabapentin

Initiating gabapentin (or any weight‑gain‑inducing anticonvulsant) in a patient with suspected OSA before confirming the diagnosis is likely to exacerbate the condition through medication‑related weight gain and provides no therapeutic benefit for the sleep disorder 27.